{"filings":[{"id":786956,"accession_number":"0001193125-26-251951","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-06-01T22:35:49+00:00","items":["8.01","9.01"],"status":"ready","headline":"Teleflex prices $500M 5.875% senior notes due 2032 to refinance 2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $500M aggregate principal of 5.875% senior notes due 2032 at 100% of par.","Net proceeds plus cash on hand to redeem all outstanding 4.625% Senior Notes due 2027.","Offering expected to close June 15, 2026, subject to customary closing conditions.","Notes guaranteed by certain domestic subsidiaries; offered privately to QIBs and non-U.S. persons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759725,"accession_number":"0001193125-26-249764","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-06-01T11:59:04+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Teleflex announces $500M senior notes offering to refinance 2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Teleflex commenced offering of $500M senior notes due 2032; proceeds plus cash to redeem all $500M of 4.625% notes due 2027.","Offering is private Rule 144A/Reg S; interest rate and terms to be set at pricing.","Exhibit 99.2 shows FY2025 adjusted EBITDA of $530.9M from continuing ops ($906.2M total); proforma EBITDA $650.7M.","As of March 31, 2026, pro forma total debt after offering would be $2.825B; company also executed $1.0B share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":698116,"accession_number":"0001193125-26-242184","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-05-27T21:23:02+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teleflex enters $2.2B new credit facilities; $1B revolver and $1.2B term loans","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered new $1B revolver, $500M term A-1, and $700M term A-2 credit facilities; refinances prior credit agreement.","Revolving and term A-1 mature May 26, 2031; term A-2 matures May 26, 2028.","Interest: Term SOFR + 1.125%-2.00% or base rate + 0.125%-1.00%; max total net leverage 4.50x, min interest coverage 3.00x.","Covenants include limitations on additional debt, liens, investments, and restricted payments, with exceptions for acquisitions and dispositions.","Agreement references pending Acute Care Disposition and OEM Disposition, affecting certain thresholds and amounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554685,"accession_number":"0000096943-26-000068","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-05-20T20:14:35+00:00","items":["5.07"],"status":"ready","headline":"Teleflex stockholders re-elect all seven directors and approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees received >96% of votes cast (excluding broker non-votes).","Advisory vote on executive compensation passed with ~96% support (38,990,583 for, 1,632,219 against).","Ratification of PwC as independent auditor for 2026 approved with ~95% of votes cast (40,460,649 for).","No contested items; all proposals passed with substantial majorities.","Broker non-votes noted on director elections and say-on-pay, but not on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100002,"accession_number":"0000096943-26-000048","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teleflex Q1 revenue up 5.1% pro forma; GAAP EPS $(0.11); maintains FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing ops $548.3M, up 32.3% reported, +5.1% pro forma adjusted constant currency.","GAAP diluted EPS from continuing ops $(0.11) vs $1.14 prior year; adjusted diluted EPS $1.39 vs $1.44.","FY26 guidance reaffirmed: GAAP rev growth 14.4%-15.4%, adjusted EPS $6.25-$6.55, including $90M stranded costs.","Jason Weidman appointed President and CEO effective June 8, 2026; $1B share repurchase program and $800M debt paydown planned.","Strategic divestitures of Acute Care, Interventional Urology, and OEM businesses expected to close H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":548262000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100001,"accession_number":"0000096943-26-000042","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Teleflex appoints Jason Weidman as President and CEO effective June 8, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Weidman succeeds interim CEO Stuart Randle, who remains on the board; Weidman to join board on start date.","Weidman previously SVP and President at Medtronic, leading coronary & renal denervation and aortic/peripheral/venous units.","Compensation includes $1M base salary, 125% target bonus, $7M annual equity target (from 2027), $7M sign-on RSUs (4-yr vest), and $1M stock options (3-yr vest).","Eligible for up to $800K cash payment to replace forfeited incentive from prior employer and relocation benefits.","Chairman cites $1B share buyback and $800M debt paydown intended after close of sale transactions as part of transformation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116331,"accession_number":"0000096943-26-000036","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Teleflex responds to Irenic; reaffirms $1.8B sale proceeds for $1B buyback, $800M debt paydown, $50M cost savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale transactions of Acute Care, Interventional Urology, and OEM on track for H2 2026 close.","Expected net proceeds of ~$1.8B after tax to fund $1.0B share repurchase and $800M debt paydown.","Multi-year restructuring targets ~$50M annual pre-tax cost savings by mid-2028.","Board has not rebuffed acquirer approaches; will consider bona fide proposals.","CEO search ongoing; interim CEO Stu Randle leading restructuring plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116330,"accession_number":"0000096943-26-000031","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Teleflex updates on OEM and Acute Care divestitures; FTC Second Request for urology deal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["OEM HSR waiting period expired March 13, 2026; closing anticipated in Q3 2026.","Acute Care and Urology deal received FTC Second Request on March 11, extending HSR review.","Company and Intersurgical cooperating with FTC; close expected in H2 2026.","Both transactions, announced Dec 9, 2025, are separate and subject to other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116329,"accession_number":"0000096943-26-000011","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","2.05","9.01"],"status":"ready","headline":"Teleflex reports FY2025 adjusted EPS $6.98; FY2026 guidance $6.25-$6.55; restructuring plan saves $48M-$52M annually","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue from continuing ops $1,992.7M (+17.2% YoY); adjusted revenue $1,983.7M (+16.3%).","GAAP diluted EPS from continuing ops $1.31 (vs $1.21); adjusted diluted EPS $6.98 (vs $6.42).","FY2026 guidance: pro forma adjusted constant currency revenue growth 4.5%-5.5%; adjusted EPS $6.25-$6.55, down from $6.98.","Restructuring plan approved: $31M-$37M total charges, annual pre-tax savings $48M-$52M, substantially complete by mid-2028.","Strategic divestitures expected close H2 2026; ~$1.8B after-tax proceeds; $1B share repurchase authorized."],"consensus_eps_estimate":null,"consensus_eps_actual":-20.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":1992713000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116328,"accession_number":"0000096943-26-000006","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teleflex enters separation agreement with ex-CEO Kelly; transition period through March 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Liam Kelly departed Jan 7, 2026; separation agreement signed Jan 23, 2026.","Kelly resigned from Board effective Jan 23, 2026.","Transition period through March 31, 2026 for transition services.","During transition, Kelly receives base salary, benefits, 2025 bonus when paid, and vesting of equity awards scheduled during transition.","Kelly remains subject to restrictive covenants from existing severance agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116327,"accession_number":"0000096943-26-000003","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Teleflex CEO Liam Kelly out, interim CEO Stuart Randle appointed; 2025 revenue guide cut","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Liam Kelly departs as President and CEO effective Jan 7, 2026; Stuart Randle appointed interim CEO.","Dr. Stephen Klasko named independent Board Chair; Spencer Stuart engaged for permanent CEO search.","Preliminary FY2025 revenue $3.270B–$3.278B, below prior guidance of $3.305B–$3.320B.","Revenue shortfall driven by softer demand for intra-aortic balloon pumps/catheters and order delays."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132792,"accession_number":"0001193125-25-312941","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Teleflex sells Acute Care, Interventional Urology, and OEM businesses for $2.03B; authorizes $1B buyback","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total cash consideration $2.03B: OEM business to Montagu/Kohlberg for $1.5B; Acute Care and Interventional Urology to Intersurgical for $530M.","Net after-tax proceeds expected ~$1.8B; primarily used for share repurchases and debt reduction.","Board authorized $1B share repurchase program, funded from transaction proceeds.","Transactions expected to close in H2 2026, subject to regulatory approvals and customary conditions.","Teleflex will focus on remaining core businesses: Vascular Access, Interventional, and Surgical, targeting mid-single-digit growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132791,"accession_number":"0000096943-25-000136","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teleflex Reports Q3 2025 Revenue Growth but GAAP Loss; Lowers Full-Year Guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue $913.0M up 19.4% YoY; adjusted revenue $892.9M up 16.8% (adjusted constant currency up 15.3%).","GAAP diluted EPS from continuing operations $(9.24) vs $2.36 prior year; adjusted diluted EPS $3.67 vs $3.49.","Full-year 2025 guidance: GAAP revenue growth narrowed to 9.1%-9.6%; adjusted constant currency revenue growth lowered to 6.9%-7.4%.","GAAP EPS from continuing operations guidance lowered to $(4.42)-$(4.22); adjusted EPS narrowed to $14.00-$14.20.","Company continues separation into RemainCo and NewCo; potential sale of NewCo is primary focus."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":2394579000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149327,"accession_number":"0000096943-25-000112","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teleflex Q2 adj. EPS $3.73 beats $3.42 YoY; raises FY outlook on BIOTRONIK deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue $780.9M (+4.2% YoY); adjusted constant currency revenue growth +1.0%.","GAAP diluted EPS $2.77 vs $1.69; adjusted diluted EPS $3.73 vs $3.42.","Full-year GAAP revenue growth guidance raised to 9.0%-10.0% (from 1.3%-2.3%) due to BIOTRONIK acquisition.","FY adjusted diluted EPS guidance raised to $13.90-$14.30 from $13.20-$13.60.","Interventional segment revenue surged 20.4% as reported; OEM and Interventional Urology each declined over 8%."],"consensus_eps_estimate":null,"consensus_eps_actual":4.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1481558000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168360,"accession_number":"0000096943-25-000107","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teleflex increases delayed draw term loan facility by $200M to $700M for Vascular Intervention acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment to Credit Agreement added $200M in delayed draw term loans, bringing total commitments to $700M.","Funds available upon consummation of the acquisition of MS Holding II SE's Vascular Intervention business.","Amendment dated June 24, 2025, with JPMorgan Chase Bank as administrative agent and several lenders.","No material changes to other terms of the credit agreement beyond the commitment increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168359,"accession_number":"0000096943-25-000099","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Teleflex amends bylaws to allow stockholder written consent; annual meeting votes pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bylaws amended to remove prohibition on stockholder action by written consent, effective May 9, 2025.","All nine director nominees elected; highest against votes for Stephen K. Klasko (14.1M against).","Advisory say-on-pay approved: 29.0M for, 10.4M against.","Ratification of PwC as auditor for 2025 approved: 39.7M for, 1.4M against.","Stockholder proposal to lower special meeting holding requirement defeated: 4.6M for, 34.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168358,"accession_number":"0000096943-25-000074","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teleflex Q1 adjusted EPS $2.91 (down 9.3% YoY); cuts FY adjusted EPS guidance to $13.20-$13.60 on $55M tariff hit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $700.7M (-5.0% reported, -3.8% adj constant currency); GAAP EPS $2.07, adjusted EPS $2.91 (down from $3.21).","FY2025 adjusted EPS guidance cut to $13.20-$13.60 (from $13.95-$14.35) on $55M tariff hit; partially offset by $300M buyback.","Completed $300M accelerated share repurchase on April 9; also exploring potential sale of NewCo in parallel with spin separation.","Segment weakness: OEM -26.8%, Interventional Urology -10.7%, Anesthesia -8.6% adj constant currency; Interventional +3.2% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":700669000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185532,"accession_number":"0000096943-25-000033","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Teleflex enters $300M accelerated share repurchase agreement with JPMorgan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $300M ASR with JPMorgan; initial delivery of shares worth 80% of repurchase price based on Feb 27 close.","Final share count based on VWAP during ASR term, less discount; settlement due in Q2 2025 or earlier.","Repurchase funded by revolving credit borrowings under existing senior credit facility.","Part of previously announced $500M share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185531,"accession_number":"0000096943-25-000025","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","2.03","2.02","5.02","7.01","9.01"],"status":"ready","headline":"Teleflex reports Q4 adj EPS $3.89 (+15%); plans two-company split and BIOTRONIK acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 GAAP EPS from cont. ops. $(2.95) vs $0.66; adj EPS $3.89 vs $3.38 (+15.1%). Full-year adj EPS $14.01.","2025 guidance: adj EPS $13.95-$14.35; adj constant currency revenue growth 1%-2%.","Plans tax-free separation into RemainCo (Vascular Access, Interventional, Surgical) and NewCo (Urology, Acute Care, OEM); completion expected mid-2026.","Definitive agreement to acquire substantially all of BIOTRONIK's Vascular Intervention business; $500M delayed draw term loan facility secured.","CFO Thomas Powell retiring Apr 1, 2025; John R. Deren succeeds as EVP & CFO effective Apr 2, consulting for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202119,"accession_number":"0000096943-24-000146","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teleflex Q3 GAAP EPS $2.36, adj $3.49; cuts FY revenue growth guidance to 2.9-3.4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP revenue $764.4M, +2.4% YoY; GAAP diluted EPS $2.36 vs $2.91; adjusted diluted EPS $3.49 vs $3.64.","Lowers FY2024 GAAP revenue growth guidance to 2.90%-3.40% (from 3.40%-4.40%); adjusted constant currency growth guidance cut to 3.5%-4.0%.","Raises FY2024 GAAP EPS guidance to $6.65-$6.95 (from $6.43-$6.83); adjusted EPS guidance $13.90-$14.20.","Interventional Urology (+13.3%) and Interventional (+11.8%) drove growth; OEM soft at +0.3%; Other category fell 28% due to Italian payback reserve.","Board authorized $500M share repurchase; $200M accelerated share program in Q3; net leverage 1.7x."],"consensus_eps_estimate":null,"consensus_eps_actual":4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":2251915000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218156,"accession_number":"0000096943-24-000140","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Teleflex CFO adopts 10b5-1 plan for up to 53,754 shares starting Dec 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CFO Thomas Powell entered a 10b5-1 trading plan allowing sale of up to 53,754 shares.","Shares represent ~31% of Powell's total holdings including options and RSUs.","Sales begin December 2024; may extend to November 2025 if minimum price thresholds unmet.","Plan is for financial planning purposes; shares acquired via exercised stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218155,"accession_number":"0000096943-24-000134","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Teleflex enters $200M accelerated share repurchase with Bank of America, scheduled to conclude Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $200M to Bank of America on Aug 5, 2024, for initial delivery of shares valued at 80% of repurchase price based on Aug 1 closing price.","Final repurchase quantity will be determined by volume-weighted average prices during the ASR term, with potential additional shares or cash adjustment.","Funded with revolving credit borrowings under existing senior credit facility and cash on hand.","Part of previously announced $500M share repurchase program; ASR expected to terminate in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218154,"accession_number":"0000096943-24-000128","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teleflex Q2 adjusted revenue $763.5M (+2.7%); raises FY adj EPS guidance to $13.80-$14.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue $749.7M (+0.9% YoY); adjusted revenue $763.5M (+2.7% YoY, +3.4% constant currency).","GAAP diluted EPS $1.69 vs $2.35 prior; adjusted diluted EPS $3.42 vs $3.41 prior.","Raises FY adjusted constant currency revenue growth guidance to 4.25%-5.25%; lowers GAAP EPS guidance to $6.43-$6.83.","Board authorized $500M share repurchase program, including $200M accelerated share repurchase.","CEO cites strong Barrigel momentum and Palette Life Sciences integration on track."],"consensus_eps_estimate":null,"consensus_eps_actual":2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1487540000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238119,"accession_number":"0000096943-24-000078","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.02","5.07","8.01"],"status":"ready","headline":"Teleflex CEO Liam Kelly adopts 10b5-1 plan to sell up to 36,464 shares (9% of holdings)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Liam Kelly entered Rule 10b5-1 plan to sell up to 36,464 shares acquired via options expiring 2025; sales in Nov and Dec 2024.","Compensation Committee approved salary increase for VP James Winters to $474,181 from $421,500, plus $200,000 equity grant (55% options, 25% RSUs, 20% PSUs).","At annual meeting, all six director nominees elected, say-on-pay approved (~93% for), shareholder proposal to lower special meeting threshold defeated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238118,"accession_number":"0000096943-24-000068","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teleflex Q1 revenue $737.8M (+3.8% YoY); adjusted EPS $3.21 vs $3.09; raises FY adjusted EPS low end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS from continuing ops $0.33 vs $1.63 prior year, reflecting $1.69 pension settlement charge.","Adjusted diluted EPS $3.21 vs $3.09; GAAP revenue growth guidance lowered to 3.35%-4.35% due to FX impact.","Constant currency revenue growth guidance reiterated at 3.75%-4.75%; GAAP EPS guidance raised to $6.87-$7.22.","Segment: Americas -1.4%, EMEA +11.4%, Asia +7.0%, OEM +13.9%; Interventional +15.2%, Other -26.7% from product disc.","Cash $237.4M; inventory $627.9M; D&A $66.9M for Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":737849000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255587,"accession_number":"0000096943-24-000027","cik":96943,"company_name":"TELEFLEX INC","ticker":"TFX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teleflex Reports Q4 2023 Revenue of $773.9M, Full Year Revenue $2,974.5M; Provides 2024 Guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS from continuing operations was $0.66, down from $1.65 in prior year; adjusted EPS was $3.38 vs $3.52.","Full year constant currency revenue growth of 6.5% driven by Asia (+17.6%) and OEM (+18.9%) segments.","2024 adjusted diluted EPS guidance range of $13.55 to $13.95, representing 0.2% to 3.2% year-over-year growth.","Cash and cash equivalents at Dec 31, 2023 were $222.8 million, down from $292.0 million a year earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":7.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":2974489000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5757783520.587611,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}